Johnson & Johnson (JNJ) Debt Components
- 2026-06-28: Commercial PaperUSD (m); Short-term DebtUSD $11.69B; Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m).
- 2026-03-29: Commercial PaperUSD (m); Short-term DebtUSD $17.46B; Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m).
- 2025-12-28: Commercial PaperUSD (m); Short-term DebtUSD $8.49B; Long-term Debt, Current MaturitiesUSD (m); Debt, CurrentUSD (m).
- 2025-12-28: Commercial PaperUSD (m); Short-term DebtUSD (m); Long-term Debt, Current MaturitiesUSD $2.00B; Debt, CurrentUSD $8.50B.
Johnson & Johnson Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Commercial Paper USD | Short-term Debt USD | Long-term Debt, Current Maturities USD | Debt, Current USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Interest Rate, Effective Percentage pure | Debt Instrument, Face Amount USD | Debt Instrument, Interest Rate During Period pure | Debt Instrument, Convertible, Interest Expense (Deprecated 2013-01-31) USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | (m) | $11.69B | (m) | (m) | $37.34B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-29 | (m) | $17.46B | (m) | (m) | $37.53B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |